1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Vital Signs The Analyst%s Perspective - October 2015 Issue

Vital Signs The Analyst%s Perspective - October 2015 Issue

  • December 2015
  • -
  • Frost & Sullivan
  • -
  • 5 pages

2015 Mammogram Guidelines Have Changed
Source: Journal of American Medical Association, October 20, 2015
On October 20, 2015, the American Cancer Society (ACS) announced an update to its recommended breast cancer screening guidelines for women with average risk of breast cancer. In the new guidelines, the ACS
recommended that “most women should begin annual screening at age 45 instead of age 40, and switch to every other year at age 55.” Mammograms can yield false-positive results, requiring additional testing or over
testing. Also, mammograms can detect very low-risk cancers that would never cause women health problems had they never been treated, resulting in many women receiving treatment who would not have otherwise
needed it, hence, over treatment.

The Analyst’s Perspective by Barbara Gilmore, Senior Industry Analyst, Life Sciences
The ACS is recommending screening for various cancers in an effort to detect cancers early, when they are easier to treat and cure. Breast cancer is the second-leading cause of cancer death in women in the United
States, and preventative screening can be beneficial. The sooner cancers can be diagnosed and treated, the higher the chance of survival or cure. In the US, there are different screening recommendations coming
from different organizations. In 2009, the US Preventative Services Task Force (USPSTF) recommended and currently recommends that women do not start getting breast mammograms until age , and then only get
screened every two years, because too many screens may lead to over diagnosis and over treatment. The ACS recommends women should be screened more frequently based on their belief that screening catches cancers at earlier stages.

What does this mean? In the long run, large sums of money will be saved with the reduced numbers of mammograms and unnecessary over treatments. Until 2015, most studies of breast cancer screening had
been performed on women older than years in the Medicare population. In 2015, physicians at Harvard Medical School and Boston Children’s studied the costs of false-positive mammograms and breast cancer over
diagnoses among women aged , based on expenditure data from a major US healthcare insurance plan for the years 2011-2013. The costs associated with false-positive mammograms and over diagnoses were
reported to be in excess of $ billion per year. It is important for women to recognize the risk factors for breast cancer, including a genetic predisposition, breast density, and family history, in making decisions about
how frequently they would have breast screens. Knowledge of the total picture will help physicians make their patient care more personalized. The women who are most at risk and would benefit from the screening should be screened. The costs associated with screening and over treatment are substantial. How much money will be saved? Time will tell.

Table Of Contents

Vital Signs The Analyst%s Perspective - October 2015 Issue
2015 Mammogram Guidelines Have Changed.. 2
NeoGenomics to Acquire Clarient from GE 3
Tute Genomics Acquires Knome. 4

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 10 125
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6 995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Ovarian Cancer: Analytical Tool

August 2016 $ 7 125

Download Unlimited Documents from Trusted Public Sources

Ovarian Cancer Statistics in the UK

  • October 2016
    39 pages
  • Ovarian Cancer  



  • United Kingdom  


View report >

Cancer Statistics in the US

  • October 2016
    9 pages
  • Pathology  


  • United States  

View report >

Cancer Statistics in the US and North America, Weekly Update

  • October 2016
    88 pages
  • Cancer  

  • United States  

    North America  

View report >

Related Market Segments :

Breast Cancer


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.